Story perspectives

NZ Delay Approving RSV Antibody Risks Thousands of Children

7/6/2026

Summary

Story summary

Clinicians at Kidz First Hospital say New Zealand’s delay in approving the RSV antibody nirsevimab leaves children vulnerable to preventable hospitalisations.
Health New Zealand reported 1,558 child RSV hospitalisations in the year to June 2025, with Medsafe requesting information after its initial assessment and Pharmac’s advisory committee recommending funding despite cost concerns.
Paediatricians noted 1,548 respiratory admissions and 90 rheumatic-fever cases at Kidz First last year, attributing many to crowded housing conditions.

1 of 1

Story summary

Clinicians at Kidz First Hospital say New Zealand’s delay in approving the RSV antibody nirsevimab leaves children vulnerable to preventable hospitalisations.
Health New Zealand reported 1,558 child RSV hospitalisations in the year to June 2025, with Medsafe requesting information after its initial assessment and Pharmac’s advisory committee recommending funding despite cost concerns.
Paediatricians noted 1,548 respiratory admissions and 90 rheumatic-fever cases at Kidz First last year, attributing many to crowded housing conditions.